On the other hand, pasireotide (PAS), which is a second generation SRL approved for treatment of GH-secreting and adrenonocorticotropic hormone (ACTH)-secreting pituitary adenomas, is still under evaluation for NENs. The gene discussed is POMC; the disease is pituitary gland adenoma.